Zhang Zhiqiao, Ouyang Yanling, Huang Yiyan, Wang Peng, Li Jing, He Tingshan, Liu Qingbo
1Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, 528308 Guangdong China.
2Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical University, Shunde, 528308 Guangdong China.
Cancer Cell Int. 2019 Jul 4;19:174. doi: 10.1186/s12935-019-0890-2. eCollection 2019.
Accumulated evidences have demonstrated that long non-coding RNAs (lncRNAs) are correlated with prognosis of patients with hepatocellular carcinoma. The current study aimed to develop and validate a prognostic lncRNA signature to improve the prediction of overall survival in hepatocellular carcinoma patients.
The study cohort involved 348 hepatocellular carcinoma patients with lncRNA expression information and overall survival information. Through gene mining approach, the current study established a prognostic lncRNA signature (named LncRNA risk prediction score) for predicting the overall survival of hepatocellular carcinoma patients.
The current study built a predictive nomogram based on ten prognostic lncRNA predictors through Cox regression analysis. In model group, the Harrell's concordance indexes of LncRNA risk prediction score were 0.811 (95% CI 0.769-0.853) for 1-year overall survival, 0.814 (95% CI 0.772-0.856) for 3-year overall survival and 0.796 (95% CI 0.754-0.838) for 5-year overall survival respectively. In validation cohort, the Harrell's concordance indexes of LncRNA risk prediction score were 0.779 (95% CI 0.737-0.821), 0.828 (95% CI 0.786-0.870) and 0.796 (95%CI 0.754-0.838) for 1-year survival, 3-year survival and 5-year survival respectively. LncRNA risk prediction score could stratify hepatocellular carcinoma patients into low risk group and high risk group. Further survival curve analysis demonstrated that the overall survival rate of high risk patients was significantly poorer than that of low risk patients (< 0.001).
In conclusion, the current study developed and validated a prognostic signature to predict the individual mortality risk for hepatocellular carcinoma patients. LncRNA risk prediction score is helpful to identify the patients with high mortality risk and optimize the individualized treatment decision. The web calculator can be used by click the following URL: https://zhangzhiqiao2.shinyapps.io/Smart_cancer_predictive_system_HCC_3/.
越来越多的证据表明，长链非编码RNA（lncRNAs）与肝细胞癌患者的预后相关。本研究旨在开发并验证一种预后lncRNA特征，以改善对肝细胞癌患者总生存期的预测。
研究队列包括348例有lncRNA表达信息和总生存期信息的肝细胞癌患者。通过基因挖掘方法，本研究建立了一种预后lncRNA特征（命名为LncRNA风险预测评分）来预测肝细胞癌患者的总生存期。
本研究通过Cox回归分析基于10个预后lncRNA预测因子构建了一个预测列线图。在模型组中，LncRNA风险预测评分的Harrell一致性指数对于1年总生存期为0.811（95%CI 0.769-0.853），对于3年总生存期为0.814（95%CI 0.772-0.856），对于5年总生存期为0.796（95%CI 0.754-0.838）。在验证队列中，LncRNA风险预测评分对于1年生存期、3年生存期和5年生存期的Harrell一致性指数分别为0.779（95%CI 0.737-0.821）、0.828（95%CI 0.786-0.870）和0.796（95%CI 0.754-0.838）。LncRNA风险预测评分可将肝细胞癌患者分为低风险组和高风险组。进一步的生存曲线分析表明，高风险患者的总生存率显著低于低风险患者（<0.001）。
总之，本研究开发并验证了一种预后特征，以预测肝细胞癌患者的个体死亡风险。LncRNA风险预测评分有助于识别高死亡风险患者并优化个体化治疗决策。可通过点击以下网址使用网络计算器：https://zhangzhiqiao2.shinyapps.io/Smart_cancer_predictive_system_HCC_3/ 。
